warenn das deine news? muhahahahahahahaha!!!!
ich glaube, du hast da aktienrückkauf mit aktienausgabe verwechselt.
so langsam kommen eure ganzen lügen ans tageslicht!
broker, vielleicht solltest du deine hahnebüchenen aussagen mal beweisen, ansonsten könnte man die böse absicht unterstellen.
ich habe damals dann alle mails von gonzales ins board gestellt und somit meinen damaligen optimismus begründet.
von dir hört man immer nur: wartet ab, ihr werdet es sehen.
broker, du bist ein ganz übler pusher!!!!!!!!!!!!!!!!!!!!!
sieh dir mal das filing von heute an:
SEC Filings
S-3
CALYPTE BIOMEDICAL CORP filed this Form S-3 on 04/27/05
.
.
.
CALYPTE BIOMEDICAL CORPORATION
39,588,810 Shares of common stock, $0.03 Par Value
o This Prospectus relates to the resale of our common stock by the selling
security holders, all of whom were issued securities pursuant to an
exemption under either Regulation D or Regulation S, of up to 39,588,810
shares of our common stock.
We have previously registered all of the shares included in this Prospectus,
including:
o 28,767,500 shares of our common stock, including 20,000,000 shares
that have been previously issued to selling security holders in
connection with an aggregate $9,300,000 May 2004 PIPE transaction at
$0.40 per share and an additional 8,767,500 shares underlying
warrants to purchase our common stock at $0.50 per share issued in
conjunction therewith;
o 4,002,800 shares of our common stock, including 1,250,000 shares
that have been previously issued to a selling security holder in
connection with an aggregate $1,488,000 PIPE transaction at $0.40
per share, and an additional 2,752,800 shares underlying warrants to
purchase our common stock at $0.50 per share issued in conjunction
therewith;
o 3,100,801 shares of our common stock previously issued to a selling
security holder upon the conversion of an aggregate principal amount
of $800,072 of our 10% convertible debentures, including accrued
interest, extension fees and other amounts;
o 1,275,000 shares of our common stock underlying warrants issued to
selling security holders in connection with a $10,000,000 5%
Promissory Note Commitment Agreement and subsequent amendments
thereof;
o 1,172,205 shares of our common stock previously issued to a selling
security holder in connection with a License Agreement and
Technology Transfer Agreement (the "License Agreement");
o 641,710 shares of our common stock that may be issued to selling
security holders upon the conversion of the remaining $60,000
aggregate principal amount of our 12% convertible debentures
including accrued interest and other amounts;
o 528,794 shares of our common stock underlying warrants or other
agreements between us and certain selling security holders in
connection with which we have obtained goods and services; and
o 100,000 shares of our common stock underlying a warrant issued to a
selling security holder as additional consideration in a convertible
debenture transaction.
Thread abonnieren
